On February 7, 2022 Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson’s disease, reported that the company will report 2H and Full Year report 2021 and hold a live webinar (in English) for investors, analysts and media on (Press release, Herantis Pharma, FEB 7, 2022, View Source,c3499761 [SID1234607777]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thursday, March 3rd, 2022, at 10:00 EET / 9:00 CET.

Herantis will publish the company’s 2H and Full Year 2021 report on March 3, 2022, at 8:00 EET /7:00 CET.

The management will present Herantis and comment on the 2H and Full Year 2021 Report followed by a live Q&A session. Please join the webinar a few minutes in advance.